Are Things Looking Up For Ginkgo Bioworks Holdings Inc (NYSE: DNA)?

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

The company is listed on the NYSE and operates within the Biotechnology industry segment. The current market capitalization of Ginkgo Bioworks Holdings Inc is $3.04B. A total of 21.42 million shares were traded on the day, compared to an average of 21.67M shares.

Insider Activity

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, DNA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 36 BUYs and 214 SELLs from insiders. Insiders purchased 1,546,736 shares during that period but sold 12,395,120.

In the most recent transaction, Dmytruk Mark E. sold 39,569 shares of DNA for 1.21 per share on Feb 02. After the transaction, the insider now owns 761,737 company shares. In a previous transaction on Jan 04, Kelly Jason R sold 100,000 shares at 1.55 per share. DNA shares that the insider owns now total 3,894,680.

Among the insiders who sold shares, Kelly Jason R disposed of 100,000 shares on Jan 03 at a per-share price of $1.54. This resulted in the insider holding 3,994,680 shares of DNA after the transaction. In another insider transaction, Dmytruk Mark E. sold 45,794 shares at $1.54 per share on Jan 03. Company shares held by the insider now total 716,098.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for DNA in the last 3 months, the mean price target is $3.02 with high estimates of $7.00 and low estimates of $1.10. In terms of 52-week highs and lows, DNA has a high of $2.55 and a low of $1.12.

As of this writing, DNA has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.06 per share and a lower estimate of -$0.14. The company reported an EPS of -$0.09 in the last quarter, which was -12.50% lower than expectations of -$0.08.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. DNA’s latest balance sheet shows that the firm has $1.55B in Cash & Short Term Investments as of fiscal 2021. There were $23.03M in debt and $134.76M in liabilities at the time. Its Book Value Per Share was $0.68, while its Total Shareholder’s Equity was $1.57B.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNA is Buy with a score of 3.13.

Most Popular

Related Posts